HCP 09
Medical Oncologist · United States · Attending physician
Illustrative synthetic data for prototype demonstration — not real clinical findings.
Discussion summary
Early adopter where data are strong; interested in ctDNA-guided decisions and sequencing.
Key themes
Pre / post perception
Overall perception shiftPre-congress vs post-congress
4 improved · 1 declined
Perception of clinical efficacy
Confidence in the evidence
Safety / tolerability perception
Likelihood to prescribe
Familiarity with treatment
Competitive perception
Illustrative synthetic measures. Movement is shown as an observed pre/post shift, not a causal effect of the congress.
KBQs discussed
Position against each predefined questionClinical significance of the primary endpoint
What is the expert consensus regarding the clinical significance of the study’s primary endpoint results?
“What matters is that the benefit looks clinically meaningful, not just statistically significant.”
Safety, tolerability and willingness to prescribe
How do HCP perceptions of the trial’s safety and tolerability profile impact their willingness to adopt and prescribe the treatment?
“The tolerability is manageable in my hands — I would prescribe this without much hesitation.”
Use in node-positive populations
What is the clinical consensus among HCPs regarding the use of CDK4/6 inhibitors in node-positive patient populations?
“The absolute benefit in this group is enough to justify the exposure for me.”
Sequencing after adjuvant recurrence
How do clinicians approach treatment sequencing following recurrence on an adjuvant CDK4/6 inhibitor?
“It depends on the interval — a late recurrence is a very different conversation from an early one.”
Compelling nature of the primary endpoint
How compelling are the primary endpoint findings in driving prospective prescribers to select this treatment over existing options?
“I read it in the context of everything else available, not in isolation.”
Perception of safety and tolerability
How do experts perceive the safety and tolerability profile demonstrated in the trial?
“It is acceptable, as long as routine monitoring is feasible in the clinic.”